Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Effectiveness of Bosentan in the Treatment of Systemic Sclerosis-Related Digital Ulcers: Systematic Review and Meta-Analysis Publisher



Hosseinbalam M1 ; Nouri R2 ; Farajzadegan Z3 ; Mottaghi P1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Internal Medicine, Medical School, Isfahan University of Medical Sciences, Isfahan, Iran
  2. 2. Health Information Technology Research Center, School of Management and Medical Information Sciences, Isfahan University of Medical Sciences, Isfahan, Iran
  3. 3. Department of Community Medicine, Faculty of Medicine, Child Growth and Development Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

Source: Journal of Research in Medical Sciences Published:2023


Abstract

Materials and Methods: The aim of the present systematic review and meta-analysis was to evaluate the therapeutic efficacy of bosentan, a dual endothelin receptor antagonist, for systemic sclerosis (SSc) patients with digital ulcers (DUs). Methods: A systematic search of MEDLINE, Embase, Web of Science, and Scopus was done using appropriate keywords till September 2021. Weighted mean difference (WMD) as the effect of therapeutic efficacy of bosentan on continuous outcomes was an estimate. Furthermore, the pooled prevalence of diffuse SSc and limited SSc was computed. Fixed or random effects models when appropriate were used for data synthesis. Results: Totally, 469 patients, with a mean age ranging from 48.1 to 63.7 years, from 8 studies were included in the systematic review and meta-analysis. The pooled frequency of diffuse SSc and limited SSc was 56% (95% confidence interval [CI]: 39%, 73%) and 44% (95% CI: 27%, 61%). The pooled prevalence of new DUs following bosentan treatment was 21% (95% CI: 10%, 33%). The results of the meta-analysis showed a pooled mean decrease of WMD: -0.09 (95% CI: -0.020, 0.02, P= 0.10), WMD: -2.82 (95% CI: -5.91, 0.27, P= 0.07), and WMD: -6.65 (95% CI: -9.49, -3.82, P< 0.001) in mean SSc-Health Assessment Questionnaire, pain, and Rodnan score, respectively. Our meta-analysis also indicated a significant pooled decrease in the number of new DUs in SSc patients compared to placebo subjects (WMD: -0.89 [95% CI: -1.40, -0.37; P= 0.001]) and baseline values (WMD: -1.34 (95% CI: -1.95, -0.73; P< 0.001). Conclusion: Bosentan possibly is an efficacious treatment option for SSc-related DUs. Although further large-scale randomized clinical trials are required to confirm the preliminary finding and underlying mechanisms of action. © 2023 Wolters Kluwer Medknow Publications. All rights reserved.
Related Docs
1. The Effect of Omega-3 Supplementation on Serum Levels of Inflammatory Biomarkers and Albumin in Hemodialysis Patients: A Systematic Review and Meta-Analysis, Journal of Renal Nutrition (2020)
2. Is Fatty Acid Composition of Breast Milk Different in Various Populations? a Systematic Review and Meta-Analysis, International Journal of Food Sciences and Nutrition (2020)
3. The Role of Exposure to Phthalates in Variations of Anogenital Distance: A Systematic Review and Meta-Analysis, Environmental Pollution (2019)
4. The Antidepressant Effects of Lavender (Lavandula Angustifolia Mill.): A Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials, Complementary Therapies in Medicine (2021)
Experts (# of related papers)
View all Related Experts
Awat Feizi (4)
Roya Kelishadi (2)